Psychiatry News

An artificial intelligence model that analyzes patients’ narrative accounts after childbirth showed potential in identifying postpartum PTSD, a study showed.

NEW YORK — Last week’s news that the U.S. Drug Enforcement Administration is proposing to reclassify marijuana from Schedule I to Schedule III is an “interesting historic moment,” according to David J. Hellerstein, MD.

NEW YORK — FDA regulations and Instagram content policies designed to minimize youth exposure to content promoting electronic nicotine delivery systems are not well enforced, according to recent research.

NEW YORK — A literature review revealed that clinicians more often assigned psychotic and childhood disorder diagnoses to Black vs. white patients, according to a poster presented at the American Psychiatric Association annual meeting.

NEW YORK — Grief is a common experience that is not discussed often enough, journalist and political commentator Anderson Cooper said during the opening session of the American Psychiatric Association annual meeting.

NEW YORK — One dose of lysergide produced clinical remission of generalized anxiety disorder as soon as 4 weeks after treatment, according to a study presented at the American Psychiatric Association annual meeting.

TORONTO — Preliminary results of a project to educate practitioners about naloxone use showed it improved their knowledge of the opioid antagonist and significantly increased naloxone distribution to patients at a Los Angeles clinic.

NEW YORK — A state with retail access to cannabis reported no decline in use during the COVID-19 pandemic compared with a state having no retail access, according to research presented at the American Psychiatric Association annual meeting.

Results of a small pilot study suggest that the ketogenic diet may help counter adverse metabolic effects of psychotropic medications and improve mental health among adults with schizophrenia or bipolar disorder.

The U.S. Drug Enforcement Administration is proposing to reclassify marijuana as a less dangerous drug, moving it from a Schedule I to Schedule III substance.